Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
QJM ; 113(5): 313-319, 2020 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-31670784

RESUMEN

BACKGROUND: Osteoporosis is common, increasing as the population ages and has significant consequences including fracture. Effective treatments are available. AIM: To support proactive fracture risk assessment (FRAX) and optimizing treatment for high-risk patients in primary care. DESIGN: Clinical cohort. SETTING: November 2017 to November 2018, support was provided to 71 practices comprising 69 of 90 practices within two National Health Service Clinical Commissioning Groups areas. Total population 579 508 (207 263 aged over 50 years). PARTICIPANTS: FRAX (National Institute for Care and Clinical Excellence, NICE CG146) in (i) males aged 75 years and over, (ii) females aged 65 years and over, (iii) females aged under 65 years and males aged under 75 years with risk factors and (iv) under 50 years with major risk factors. RESULTS: A total of 158 946 met NICE CG146, 11 961 were coded with an osteoporosis diagnosis (7.5%), of those, 42% were prescribed treatment with a bone sparing agent (BSA). In total, 6942 were assessed to initiate BSA. Thirty percent of untreated osteoporosis diagnosis patients had never been prescribed BSA. Even when prescribed, 1700 people (35%) were for less than minimum recommended duration. Of the total 9784 patients within the FRAX recommended to treat threshold, 3197 (33%) were currently treated with BSA and 3684 (37%) had no history of ever receiving BSA. From untreated patients, expected incidence of 875 fractures over a 3-year period (approximately £3.4 million). Treatment would prevent 274 fractures (cost reduction: £1 274 045, with prescribing costs: saving £805 145 after 3 years of treatment). CONCLUSION: Underdiagnosis and suboptimal treatment of osteoporosis was identified. Results suggest that implementing NICE guidance and optimizing treatment options in practice is possible and could prevent significant fractures.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Osteoporosis/complicaciones , Fracturas Osteoporóticas/prevención & control , Atención Primaria de Salud , Anciano , Anciano de 80 o más Años , Densidad Ósea , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/tratamiento farmacológico , Osteoporosis/epidemiología , Fracturas Osteoporóticas/epidemiología , Medición de Riesgo/métodos , Factores de Riesgo , Medicina Estatal , Reino Unido/epidemiología
2.
Phytopathology ; 99(2): 203-8, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19159312

RESUMEN

Aphanomyces euteiches is a major soilborne oomycete pathogen that infects various legume species, including pea and alfalfa. The model legume Medicago truncatula has recently emerged as a valuable genetic system for understanding the genetic basis of resistance to A. euteiches in leguminous crops. The objective of this study was to identify genetic determinants of resistance to a broad host-range pea-infecting strain of A. euteiches in M. truncatula. Two M. truncatula segregating populations of 178 F(5) recombinant inbred lines and 200 F(3) families from the cross F83005.5 (susceptible) x DZA045.5 (resistant) were screened for resistance to A. euteiches. Phenotypic distributions observed suggested a dominant monogenic control of resistance. A major locus associated with resistance to A. euteiches, namely AER1, was mapped by bulk segregant analysis to a terminal end of chromosome 3 in M. truncatula and explained 88% of the phenotypic variation. AER1 was identified in a resistance-gene-rich region, where resistance gene analogs and genes associated with disease resistance phenotypes have been identified. Discovery of AER1 opens up new prospects for improving resistance to A. euteiches in cultivated legumes using a comparative genomics approach.


Asunto(s)
Aphanomyces/fisiología , Medicago truncatula/genética , Medicago truncatula/microbiología , Enfermedades de las Plantas/genética , Mapeo Cromosómico , Cromosomas de las Plantas , Genes de Plantas , Ligamiento Genético , Predisposición Genética a la Enfermedad , Genómica , Enfermedades de las Plantas/microbiología , Proteínas de Plantas/genética , Proteínas de Plantas/metabolismo
3.
Rev Med Interne ; 24(4): 261-5, 2003 Apr.
Artículo en Francés | MEDLINE | ID: mdl-12706784

RESUMEN

INTRODUCTION: Pourfour du Petit syndrome, rarely reported, is the opposite of Claude Bernard-Horner syndrome. EXEGESES: A 67 years old female is hospitalised for dysphagia, allowing the discovery of oesophagus carcinoma with mediastinal, pleural and costal extension. The discovery of left unilateral mydriasis associated with exophthalmos and eyelid retraction suggest Pourfour du Petit syndrome; this diagnosis is confirmed by CT-scan, finding pedicular lysis of high dorsal vertebras and intra-canalar tumoral extension. CONCLUSION: Pourfour du Petit syndrome has the same localisation value and the same aetiologies as Claude Bernard-Horner syndrome, but its mechanism proceeds byan exciting lesion of cervical sympathetic nervous system. The recognition of this entity can allow the diagnosis of pathologies that need emergency treatment.


Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/etiología , Neoplasias Esofágicas/complicaciones , Exoftalmia/etiología , Enfermedades de los Párpados/etiología , Midriasis/etiología , Enfermedades Raras/etiología , Anciano , Trastornos de Deglución/etiología , Neoplasias Esofágicas/tratamiento farmacológico , Resultado Fatal , Femenino , Humanos , Síndrome , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA